By Application
Hot products 
-
Mouse Anti-B2M Recombinant Antibody (CBYY-0050) (CBMAB-0050-YY)
-
Mouse Anti-CFL1 Recombinant Antibody (CBFYC-1771) (CBMAB-C1833-FY)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-CD24 Recombinant Antibody (ALB9) (CBMAB-0176CQ)
-
Mouse Anti-ASB9 Recombinant Antibody (1D8) (CBMAB-A0529-LY)
-
Mouse Anti-ARID1B Recombinant Antibody (KMN1) (CBMAB-A3546-YC)
-
Mouse Anti-ACTG1 Recombinant Antibody (V2-179597) (CBMAB-A0916-YC)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
-
Mouse Anti-ENO2 Recombinant Antibody (H14) (CBMAB-E1341-FY)
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Mouse Anti-Tau Recombinant Antibody (100) (CBMAB-0478CQ)
-
Mouse Anti-CALR Recombinant Antibody (CBFYC-0763) (CBMAB-C0818-FY)
-
Mouse Anti-ATP1B1 Recombinant Antibody (E4) (CBMAB-0463-LY)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-GZMA Recombinant Antibody (CBLG1-2197) (CBMAB-G5901-LY)
-
Mouse Anti-AKR1C3 Recombinant Antibody (V2-12560) (CBMAB-1050-CN)
-
Mouse Anti-GNA12 Recombinant Antibody (CBFYH-0402) (CBMAB-H1272-FY)
Lung Cancer
Fig.1 Lung cancer
Lung cancer, also named as lung carcinoma, is characterized by uncontrolled cell growth in the tissues of lung. The two major types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), which are malignant lung tumor. The most obvious symptoms are coughing (coughing up blood included), shortness of breath, chest pains and weight loss. The vast majority (85%) of lung cancer are on account of long-term tobacco smoking. Around 10–15% of cases occur in those who have never smoked before. These cases are often caused by a combination of genetic factors and exposure to harmful gas, such as: radon gas, second-hand smoke, asbestos or other forms of air pollution. Mutations in the K-ras proto-oncogene account for 10–30% of lung adenocarcinomas. Around 4% of non-small-cell lung carcinomas are considered to involve an EML4-ALK tyrosine kinase fusion gene. Tumor markers, such as CEA and CYFRA 21-1 are of great diagnostic value in primary lung cancer.
